Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma

Published:2017-06-23 Issue:1 Volume:32 Page:120-130
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Laganà A,Perumal D,Melnekoff D,Readhead B,Kidd B A,Leshchenko V,Kuo P-Y,Keats J,DeRome M,Yesil J,Auclair D,Lonial S,Chari A,Cho H J,Barlogie B,Jagannath S,Dudley J T,Parekh S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017197.pdf

Reference34 articles.

1. Röllig C, Knop S, Bornhäuser M . Multiple myeloma. Lancet 2015; 385: 2197–2208.

2. Siegel RL, Miller KD, Jemal A . Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.

3. Morgan GJ, Walker BA, Davies FE . The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335–348.

4. Szalat R, Munshi NC . Genomic heterogeneity in multiple myeloma. Curr Opin Genet Dev 2015; 30: 56–65.

5. Jonathan J, Keats DWC, Liang W, Venkata Y, Kurdoglu A, Aldrich J et al. Interim analysis of the MMRF CoMMpass Trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles. Blood 2013; 122.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of Clec11a in bone construction and remodeling;Frontiers in Endocrinology;2024-08-12

2. Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma;Nature Communications;2024-03-21

3. Identification and characterization of CLEC11A and its derived immune signature in gastric cancer;Frontiers in Immunology;2024-01-29

4. Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma;2024-01-09

5. Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-01